Shares of WUXI APPTEC Co., Ltd (02359.HK) soared 16.21% on Thursday amid reports that the Chinese biotech firm and its related companies are exploring the divestment of certain assets in response to potential U.S. restrictions.
According to a Financial Times report, WUXI APPTEC is considering selling its WUXI Advanced Therapies unit, which manufactures cell and gene therapies and has operations in the United States. The report, citing sources familiar with the matter, also indicated that WUXI Biologics is gauging interest in its European production facilities.
The reported asset sale plans come as the U.S. House of Representatives recently passed a draft of the Biosecure Act, which designates the WUXI companies as "biotechnology companies of concern" due to alleged military ties. If enacted, the legislation could bar U.S. government agencies from using funding or making contracts that involve certain biotechnology equipment or services from designated companies like WUXI.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。